AbbVie India Violates UCPMP, 2024

January 4, 2025

The recent actions of AbbVie Healthcare India Private Ltd have brought attention to the ethical standards in pharmaceutical marketing. The company was found guilty of violating the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), 2024. An anonymous report revealed that AbbVie sponsored international trips for doctors, which constituted a breach of regulations designed to promote ethical conduct in the industry.

About UCPMP 2024

The UCPMP 2024 is a regulatory framework governing interactions between pharmaceutical companies and healthcare professionals in India. It prohibits pharmaceutical companies from offering gifts, benefits, or any financial advantages to healthcare professionals and their families. The code aims to maintain transparency and ethical practices within the pharmaceutical sector.

Key Regulations of UCPMP 2024

The UCPMP 2024 explicitly forbids companies from providing travel facilities or hospitality to healthcare professionals, except in specified educational programmes. However, it does allow for the provision of informational materials and free samples, provided they meet certain conditions. This code replaces the earlier UCPMP 2014 and applies equally to medical device companies.

The Doctor-Pharma Relationship

The relationship between doctors and pharmaceutical companies has long been scrutinised due to potential conflicts of interest. Financial incentives can influence prescribing practices, even if the gifts are small. The Indian Journal of Medical Ethics marks the importance of self-awareness among doctors to mitigate these biases and uphold ethical standards.

AbbVie’s Justification and Consequences

In response to the allegations, AbbVie claimed that their actions were an ‘acceptable industry practice’ and cited a professional service agreement with the involved doctors. However, the company rejected suggestions for remedial actions, leading to repercussions. The Central Board of Direct Taxes has been tasked with evaluating the tax implications for both AbbVie and the implicated doctors.

Importance of Strict Enforcement

Experts emphasise the need for stringent enforcement of the UCPMP to prevent conflicts of interest and encourage trust in the medical community. The Indian pharmaceutical industry is a global leader, supplying a vast array of generic drugs and maintaining a strong domestic market. The industry’s growth necessitates adherence to ethical practices to sustain its reputation.

UCPMP stands for Uniform Code for Pharmaceutical Marketing Practices.
AbbVie Healthcare is a subsidiary of AbbVie Inc, based in the USA.
The Indian pharmaceutical market was valued at USD 42 billion in 2021.
India exports pharmaceuticals to over 200 countries.
The National Medical Council regulates ethical practices for Indian doctors.

Future Directions in Pharmaceutical Ethics

The ongoing scrutiny of pharmaceutical marketing practices may lead to more stringent regulations and oversight. It is crucial for the industry to adapt to these changes to ensure compliance and maintain public trust.

« Previous Post Next Post »